Cognition Supplements - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cognition supplements market size is expected to increase from USD 1.53 billion in 2025 to USD 1.64 billion in 2026 and reach USD 2.31 billion by 2031, growing at a CAGR of 7.09% over 2026-2031. This report is Segmented by Product Type (Natural Molecules, Herbal Extracts, Vitamins and Minerals, Others), Form (Capsules and Tablets, and More), Distribution Channel (Supermarkets/Hypermarkets, and More), and Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Tons).

Global Cognition Supplements Market Trends and Insights

Rising aging population and cognitive decline awareness

In 2024, 10% of the world's population was aged 65 and older, according to the World Bank. This aging population trend is further emphasized by findings from the Lancet Commission on Dementia Prevention, which identified 12 modifiable risk factors, including hypertension, diabetes, and air pollution, that collectively contribute to approximately 40% of dementia cases. These insights highlight the growing importance of cognitive supplements as complementary tools to support lifestyle interventions aimed at mitigating these risks. In response to this demand, brands are increasingly developing multi-ingredient formulations designed to address both neurotransmitter support and vascular health. This approach is effectively bridging the gap between cardiovascular and cognitive product categories. Furthermore, regulatory frameworks in high-income markets are evolving to accommodate structure-function claims related to aging. However, manufacturers must substantiate these claims with credible evidence, such as biomarkers like brain-derived neurotrophic factor or cerebral blood flow, to ensure compliance and consumer trust.

Preventive-health and wellness trend

Preventive health expenditure is undergoing a significant transformation, shifting focus from reactive disease management to proactive health optimization. This trend has gained momentum due to the rise of employer wellness programs and the increasing adoption of direct-to-consumer telehealth platforms. Subscription-based business models are effectively leveraging this shift. For example, companies like Care/of and Ritual utilize algorithm-driven quizzes to create personalized nootropic regimens for their customers. These companies then secure customer loyalty through recurring shipment models, which enhance their lifetime value metrics. Additionally, the emphasis on wellness is becoming increasingly intertwined with workplace productivity. Corporate buyers are exploring cognitive-supplement programs as part of broader initiatives that include ergonomic improvements and mental health benefits. These efforts highlight the growing recognition of brain health as a critical factor in improving employee retention and performance. Although the employer channel for such programs is still in its early stages, it presents a promising opportunity to establish bulk purchasing agreements that could bypass traditional retail margins, offering a more cost-effective and scalable solution.

Adverse-effect and drug-interaction concerns

Older adults, who are the primary users of cognitive supplements, face increased risks of herb-drug interactions due to polypharmacy. These interactions can reduce a supplement's effectiveness or cause adverse side effects. The U.S. National Institutes of Health's Office of Dietary Supplements has documented significant interactions, including Ginkgo biloba with anticoagulants, St. John's Wort with selective serotonin reuptake inhibitors, and high-dose B vitamins with metformin. Physicians often hesitate to recommend supplements because of insufficient pharmacokinetic data, which hinders their broader adoption. In 2024, the FDA's adverse-event reporting system recorded 1,847 serious incidents associated with dietary supplements, though determining causality is challenging, especially with overlapping medication use. Brands that conduct drug-interaction studies and publish their findings in reputable journals can establish a competitive edge in safety. However, these studies require years to complete and demand significant financial resources, often beyond the capacity of smaller brands. The Dietary Supplement Health and Education Act does not mandate pre-market approvals, placing the responsibility on post-market surveillance to ensure safety, which increases reputational risks if major adverse events attract media attention.

Other drivers and restraints analyzed in the detailed report include:

• Growing consumer interest in natural and plant-based solutions
• Growing prevalence of neurological disorders
• Fragmented global regulatory frameworks

Segment Analysis

In 2025, Natural Molecules held a 45.09% share of the cognition supplement market, highlighting the robust clinical evidence supporting omega-3 and phosphatidylserine. At the same time, Vitamins and Minerals are experiencing an 8.15% CAGR, driven by formulators emphasizing B-complex vitamins and magnesium threonate for their ability to manage homocysteine levels and improve synaptic density. This shift not only strengthens medical endorsements but also aligns with dietary reference intakes monitored by physicians. On the innovation front, herbal extracts such as Bacopa and Lion’s Mane leverage adaptogenic narratives, though dosage inconsistencies continue to complicate meta-analyses. Furthermore, as commodity pressures reduce margins on fish-oil concentrates, brands are turning to value-added options like krill oil enriched with astaxanthin.

Micronutrient stacks attract biohackers seeking measurable biomarker changes, while standardized herbal extracts appeal to natural-product enthusiasts. Proprietary citicoline commands a premium due to its clinical backing, but generic choline poses a threat to its market share. Recent USP monograph updates have standardized potency bands for Bacopa and ashwagandha, enabling more consistent efficacy comparisons. Ingredient suppliers investing in head-to-head trials could influence the growth of the cognition supplement market in favor of their branded actives. Additionally, amino acids like L-theanine are gaining traction as they transition from energy drinks to capsules and powders, expanding their demand across various consumer groups.

Complete Report Scope:

• By Product Type
  • Natural Molecules
  • Herbal Extracts
  • Vitamins and Minerals
  • Others
• By Form
  • Capsules and Tablets
  • Powders
  • Gummies and Chewables
• By Distribution Channel
  • Supermarkets/Hypermarkets
  • Pharmacies/Drug Stores
  • Online Retail Stores
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Rest of South America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Sweden
    • Belgium
    • Poland
    • Netherlands
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Thailand
    • Singapore
    • Indonesia
    • South Korea
    • Australia
    • New Zealand
    • Rest of Asia-Pacific
  • Middle East and Africa
    • United Arab Emirates
    • South Africa
    • Saudi Arabia
    • Nigeria
    • Egypt
    • Morocco
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

In 2025, North America held a 31.74 percent market share, driven by high per-capita spending on supplements, a robust distribution network, and a regulatory framework under the Dietary Supplement Health and Education Act that enables rapid product launches without requiring pre-market approval. The U.S. leads in innovation, with venture-backed startups like HVMN and Neurohacker Collective introducing advanced nootropic stacks and ketone esters that appeal to biohacking communities. However, the FDA's enforcement actions in 2024 and 2025, targeting unapproved disease claims and good manufacturing practice violations, have increased compliance risks, favoring larger brands with dedicated regulatory teams. In Canada, the Natural and Non-prescription Health Products Directorate requires pre-market notifications and product licensing, creating a higher entry barrier compared to the U.S., while signaling quality that appeals to risk-averse consumers. Meanwhile, Mexico's expanding middle class and proximity to U.S. supply chains are attracting cross-border e-commerce players, though inconsistent regulatory enforcement and the prevalence of counterfeit products in informal retail remain challenges.

Asia-Pacific is projected to be the fastest-growing region, with an 8.01 percent expansion forecast from 2026 to 2031. This growth is driven by aging populations in Japan and South Korea, coupled with increasing health awareness in China and India. In 2025, Japan's Ministry of Health, Labour and Welfare reported that one in four citizens is over 65, fueling demand for Foods with Function Claims that target memory and concentration without requiring pre-market approval. In 2024, China's National Medical Products Administration tightened health food registration requirements, mandating toxicology dossiers and clinical trials, which benefit multinational corporations with regulatory expertise over local startups. In 2025, India's Food Safety and Standards Authority of India introduced draft guidelines allowing Ayurvedic extracts in nutraceuticals, unlocking export opportunities for standardized Bacopa and ashwagandha while enabling domestic brands to formalize traditional-use claims. Southeast Asian countries like Thailand, Indonesia, and Singapore are attracting multinational brands seeking first-mover advantages in e-commerce and modern retail, though fragmented regulations and import tariffs complicate regional strategies. Australia and New Zealand, governed by the Therapeutic Goods Administration's complementary-medicines framework, offer mature markets with high consumer trust in third-party certifications, positioning them as ideal testing grounds for premium formulations before broader Asia-Pacific rollouts.

Europe's cognitive-supplement market benefits from the European Food Safety Authority's health-claims regulation, which requires pre-approval of structure-function claims based on peer-reviewed evidence. While this enhances credibility, it also raises entry barriers for smaller brands. The U.K., Germany, and France lead in per-capita consumption, driven by aging populations and strong pharmacy channels that provide pharmacist-led counseling on supplement use. The European Union's Novel Foods Regulation mandates pre-market safety assessments for ingredients without significant consumption history before 1997. This has slowed the introduction of emerging nootropics like Lion's Mane mushroom, prompting brands to rely on established botanicals such as Ginkgo biloba. Eastern European markets like Poland and Russia are experiencing growth as rising incomes and urbanization drive demand for preventive health products, though distribution remains concentrated in pharmacies and hypermarkets, with limited e-commerce penetration. In South America, Brazil and Argentina are seeing increased interest in traditional botanicals like Guarana and Maca, though incomplete regulatory harmonization under Mercosur and import tariffs on finished goods favor local manufacturing. The Middle East and Africa, led by the United Arab Emirates and South Africa, are emerging markets where expatriate populations and medical tourism drive demand for premium imported brands. However, the region faces challenges with limited local manufacturing capacity and evolving regulatory frameworks.

List of Companies Covered in this Report:

• Amway Corporation
• Bayer AG
• Nestle S.A. (incl. Garden of Life)
• Herbalife Nutrition Ltd.
• Reckitt Benckiser Group plc (Neuriva)
• NOW Foods
• Blackmores Ltd.
• Onnit Labs Inc.
• Quincy Bioscience
• Teva Pharmaceutical Industries Ltd.
• Himalaya Wellness Company
• Dr. Willmar Schwabe GmbH and Co. KG
• Haleon plc (Prev. GSK Consumer)
• Lonza Group
• Life Extension
• Jarrow Formulas Inc.
• Natural Factors Inc.
• Liquid Health Inc.
• Pure Encapsulations
• HVMN Inc.
• Neurohacker Collective LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support